30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Evolus Inc (EOLS)

Track

Stock chart
Ticker: EOLS Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Avelar Rui
See Remarks
1 sale — total 14,815 USD
Planned sale 20 Mar 2026
Value US$4,336,569.49 | Price 217.16 | Shares 34,614
Planned sale 20 Mar 2026
Value US$442,840.06 | Price 236.35 | Shares 7,943
Planned sale 17 Mar 2026
Value US$570,562.38 | Price 4.89 | Shares 116,720
Planned sale 17 Mar 2026
Value US$146,629.45 | Price 4.89 | Shares 29,996
Planned sale 22 Dec 2025
Value US$75,361.23 | Price 7.15 | Shares 10,539
Planned sale 22 Dec 2025
Value US$16,167.73 | Price 7.15 | Shares 2,261
Planned sale 22 Aug 2025
Value US$42,972.22 | Price 7.51 | Shares 5,722
Buy 15 Aug 2025
Value US$204,486.00 | Price 6.82 | Shares 30,000
Proposed sale 16 Jun 2025
Value US$164,052.36 | Price 9.89 | Shares 16,582
Sale 16 Jun 2025
Value US$164,054.02 | Price 9.89 | Shares 16,582
Sale 13 Jun 2025
Value US$1,119,141.25 | Price 10.05 | Shares 111,323
Proposed sale 13 Jun 2025
Value US$1,119,141.25 | Price 10.05 | Shares 111,323
Buy 9 Jun 2025
Value US$189,000.00 | Price 9.45 | Shares 20,000
Planned sale 13 May 2025
Value US$65,069.88 | Price 10.02 | Shares 6,494
Planned sale 12 May 2025
Value US$155,756.12 | Price 9.87 | Shares 15,787
Planned sale 12 May 2025
Value US$33,396.75 | Price 9.87 | Shares 3,385
Planned sale 27 Mar 2025
Value US$77,512.40 | Price 12.40 | Shares 6,251
Planned sale 18 Mar 2025
Value US$60,124.68 | Price 13.26 | Shares 4,536
Planned sale 18 Mar 2025
Value US$119,242.88 | Price 13.26 | Shares 8,996
Planned sale 18 Mar 2025
Value US$369,867.52 | Price 13.26 | Shares 27,904
Planned sale 18 Mar 2025
Value US$1,370,248.88 | Price 13.26 | Shares 103,376
Sale 12 Mar 2025
Value US$167,465.38 | Price 12.99 | Shares 12,888
Proposed sale 12 Mar 2025
Value US$167,465.46 | Price 12.99 | Shares 12,888
Planned sale 23 Dec 2024
Value US$17,211.11 | Price 10.85 | Shares 1,586
Planned sale 23 Dec 2024
Value US$113,966.65 | Price 10.85 | Shares 10,502
Planned sale 23 Dec 2024
Value US$24,438.48 | Price 10.85 | Shares 2,252
Sale 6 Sep 2024
Value US$49,074.48 | Price 14.98 | Shares 3,276
Sale 30 Aug 2024
Value US$89,251.35 | Price 15.85 | Shares 5,631
Proposed sale 6 Jun 2024
Value US$2,540,000.00 | Price 12.70 | Shares 200,000
Sale 6 Jun 2024
Value US$2,214,486.40 | Price 12.59 | Shares 175,940
Sale 5 Jun 2024
Value US$2,006,455.73 | Price 12.92 | Shares 155,278
Proposed sale 5 Jun 2024
Value US$1,972,030.60 | Price 12.70 | Shares 155,278
Sale 4 Jun 2024
Value US$1,784,685.86 | Price 12.73 | Shares 140,214
Proposed sale 4 Jun 2024
Value US$1,780,717.80 | Price 12.70 | Shares 140,214
Sale 3 Jun 2024
Value US$97,203.00 | Price 12.96 | Shares 7,500
Proposed sale 3 Jun 2024
Value US$97,200.00 | Price 12.96 | Shares 7,500
Sale 14 May 2024
Value US$84,653.52 | Price 12.60 | Shares 6,718
Sale 13 May 2024
Value US$362,012.00 | Price 12.93 | Shares 28,000
Proposed sale 13 May 2024
Value US$362,040.00 | Price 12.93 | Shares 28,000
Sale 13 May 2024
Value US$46,356.08 | Price 12.72 | Shares 3,643
Proposed sale 13 May 2024
Value US$131,584.70 | Price 12.70 | Shares 10,361
Sale 10 May 2024
Value US$204,126.99 | Price 12.72 | Shares 16,051
Sale 10 May 2024
Value US$30,814.26 | Price 12.72 | Shares 2,423
Sale 10 May 2024
Value US$43,760.57 | Price 12.72 | Shares 3,441
Sale 27 Mar 2024
Value US$86,430.96 | Price 13.86 | Shares 6,236
Sale 19 Mar 2024
Value US$78,978.06 | Price 13.92 | Shares 5,672
Sale 19 Mar 2024
Value US$1,344,604.30 | Price 13.92 | Shares 96,566
Sale 19 Mar 2024
Value US$384,349.69 | Price 13.92 | Shares 27,603
Planned sale 22 Feb 2024
Value US$100,803.73 | Price 13.08 | Shares 7,706
Planned sale 22 Feb 2024
Value US$23,820.87 | Price 13.08 | Shares 1,821
Planned sale 22 Feb 2024
Value US$23,820.87 | Price 13.08 | Shares 1,821
Sale 30 Jan 2024
Value US$156,732.77 | Price 13.14 | Shares 11,931
Proposed sale 30 Jan 2024
Value US$156,731.58 | Price 13.14 | Shares 11,931
Sale 8 Dec 2023
Value US$304,505.18 | Price 9.73 | Shares 31,300
Sale 6 Dec 2023
Value US$517,890.79 | Price 10.09 | Shares 51,348
Proposed sale 6 Dec 2023
Value US$826,480.00 | Price 10.00 | Shares 82,648
Sale 16 Oct 2023
Value US$12,679,972.50 | Price 7.50 | Shares 1,690,663
Planned sale 6 Sep 2023
Value US$30,826.60 | Price 9.70 | Shares 3,178
Planned sale 16 Aug 2023
Value US$22,706.97 | Price 10.27 | Shares 2,211
Planned sale 16 Aug 2023
Value US$151,770.06 | Price 10.27 | Shares 14,778
Planned sale 16 Aug 2023
Value US$22,706.97 | Price 10.27 | Shares 2,211
Buy 15 Aug 2023
Value US$1,296,505.47 | Price 7.41 | Shares 174,967
Planned sale 27 Mar 2023
Value US$51,751.70 | Price 8.47 | Shares 6,110
Planned sale 14 Mar 2023
Value US$126,237.42 | Price 8.47 | Shares 14,906
Planned sale 14 Mar 2023
Value US$543,796.54 | Price 8.47 | Shares 64,211
Sale 7 Feb 2023
Value US$18,593,843.50 | Price 8.50 | Shares 2,187,511
Sale 20 Jan 2023
Value US$408,954.72 | Price 11.04 | Shares 37,043
Sale 6 Oct 2022
Value US$344,418.08 | Price 8.99 | Shares 38,304
Sale 5 Oct 2022
Value US$61,289.60 | Price 8.95 | Shares 6,848
Sale 15 Sep 2022
Value US$248,104.80 | Price 10.34 | Shares 24,000
Sale 14 Sep 2022
Value US$749,673.50 | Price 10.27 | Shares 73,000
Buy 12 Sep 2022
Value US$11,755.52 | Price 10.78 | Shares 1,091
Buy 9 Sep 2022
Value US$92,182.31 | Price 10.35 | Shares 8,909
Sale 9 Sep 2022
Value US$217,910.97 | Price 10.53 | Shares 20,700
Sale 8 Sep 2022
Value US$158,979.24 | Price 10.39 | Shares 15,300
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-03-20 2026-03-20 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
34,614 -26.9%
217.16
US$4,336,569 		34,614 -26.9% 217.16 US$4,336,569
2026-03-20 2026-03-20 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
7,943 -49.4%
236.35
US$442,840 		7,943 -49.4% 236.35 US$442,840
2026-03-18 2026-03-17 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
34,755 +37.7%
309.82
US$66,607 		34,755 +37.7% 309.82 US$66,607
2026-03-18 2026-03-17 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
29,996 -6.5%
4.89
US$146,629 		29,996 -6.5% 4.89 US$146,629
2025-12-29 2025-12-22 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
10,539 -2.9%
7.15
US$75,361 		10,539 -2.9% 7.15 US$75,361
2025-12-29 2025-12-22 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
2,261 -0.6%
7.15
US$16,168 		2,261 -0.6% 7.15 US$16,168
2025-08-26 2025-08-22 PlS Planned sale
2.4
Yamagishi-Dressler Tomoko

Chief Marketing Officer

Officer
5,722 -6.0%
7.51
US$42,972 		5,722 -6.0% 7.51 US$42,972
2025-08-18 2025-08-15 B Purchase
2.2
Stewart Brady
Non-Executive Director
30,000 +51.2%
6.82
US$204,486 		30,000 +51.2% 6.82 US$204,486
2025-06-16 2025-06-16 PrS Proposed sale
2.9
DAVID MOATAZEDI

Officer; Director

Executive Director
16,582
9.89
US$164,052 		16,582 9.89 US$164,052
2025-06-16 2025-06-16 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
16,582 -4.3%
9.89
US$164,054 		16,582 -4.3% 9.89 US$164,054
2025-06-16 2025-06-13 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
111,323 -22.6%
10.05
US$1,119,141 		111,323 -22.6% 10.05 US$1,119,141
2025-06-13 2025-06-13 PrS Proposed sale
2.9
DAVID MOATAZEDI

Officer; Director

Executive Director
111,323
10.05
US$1,119,141 		111,323 10.05 US$1,119,141
2025-06-10 2025-06-09 B Purchase
3.0
White Albert G III
Non-Executive Director
20,000 +65.8%
9.45
US$189,000 		20,000 +65.8% 9.45 US$189,000
2025-05-14 2025-05-13 PlS Planned sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
6,494 -3.7%
10.02
US$65,070 		6,494 -3.7% 10.02 US$65,070
2025-05-14 2025-05-12 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
15,787 -3.1%
9.87
US$155,756 		15,787 -3.1% 9.87 US$155,756
2025-05-14 2025-05-12 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
3,385 -0.9%
9.87
US$33,397 		3,385 -0.9% 9.87 US$33,397
2025-03-28 2025-03-27 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
6,251 -1.2%
12.40
US$77,512 		6,251 -1.2% 12.40 US$77,512
2025-03-20 2025-03-18 PlS Planned sale
2.4
Yamagishi-Dressler Tomoko

Chief Marketing Officer

Officer
4,536 -4.5%
13.26
US$60,125 		4,536 -4.5% 13.26 US$60,125
2025-03-20 2025-03-18 PlS Planned sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
8,996 -4.9%
13.26
US$119,243 		8,996 -4.9% 13.26 US$119,243
2025-03-20 2025-03-18 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
27,904 -7.1%
13.26
US$369,868 		27,904 -7.1% 13.26 US$369,868
2025-03-20 2025-03-18 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
103,376 -16.7%
13.26
US$1,370,249 		103,376 -16.7% 13.26 US$1,370,249
2025-03-14 2025-03-12 S Sale
2.3
Parschauer Karah Herdman
Non-Executive Director
12,888 -28.6%
12.99
US$167,465 		12,888 -28.6% 12.99 US$167,465
2025-03-12 2025-03-12 PrS Proposed sale
2.3
Parschauer Karah Herdman

Director

Non-Executive Director
12,888
12.99
US$167,465 		12,888 12.99 US$167,465
2024-12-26 2024-12-23 PlS Planned sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
1,586 -1.1%
10.85
US$17,211 		1,586 -1.1% 10.85 US$17,211
2024-12-26 2024-12-23 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
10,502 -2.0%
10.85
US$113,967 		10,502 -2.0% 10.85 US$113,967
2024-12-26 2024-12-23 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
2,252 -0.6%
10.85
US$24,438 		2,252 -0.6% 10.85 US$24,438
2024-09-06 2024-09-06 S Sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
3,276 -2.2%
14.98
US$49,074 		3,276 -2.2% 14.98 US$49,074
2024-09-04 2024-08-30 S Sale
2.4
Yamagishi-Dressler Tomoko

Chief Marketing Officer

Officer
5,631 -6.4%
15.85
US$89,251 		5,631 -6.4% 15.85 US$89,251
2024-06-06 2024-06-06 PrS Proposed sale
2.9
MOATAZEDI DAVID

Officer

Officer
200,000
12.70
US$2,540,000 		200,000 12.70 US$2,540,000
2024-06-06 2024-06-06 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
175,940 -24.8%
12.59
US$2,214,486 		175,940 -24.8% 12.59 US$2,214,486
2024-06-06 2024-06-05 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
155,278 -22.5%
12.92
US$2,006,456 		155,278 -22.5% 12.92 US$2,006,456
2024-06-05 2024-06-05 PrS Proposed sale
2.9
MOATAZEDI DAVID

Officer

Officer
155,278
12.70
US$1,972,031 		155,278 12.70 US$1,972,031
2024-06-06 2024-06-04 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
140,214 -20.8%
12.73
US$1,784,686 		140,214 -20.8% 12.73 US$1,784,686
2024-06-04 2024-06-04 PrS Proposed sale
2.9
MOATAZEDI DAVID

Officer

Officer
140,214
12.70
US$1,780,718 		140,214 12.70 US$1,780,718
2024-06-05 2024-06-03 S Sale
2.0
Malik Vikram
Non-Executive Director
7,500 -3.0%
12.96
US$97,203 		7,500 -3.0% 12.96 US$97,203
2024-06-03 2024-06-03 PrS Proposed sale
2.0
Malik Vikram

Officer

Officer
7,500
12.96
US$97,200 		7,500 12.96 US$97,200
2024-05-15 2024-05-14 S Sale
2.2
GILL DAVID N
Non-Executive Director
6,718 -16.5%
12.60
US$84,654 		6,718 -16.5% 12.60 US$84,654
2024-05-15 2024-05-13 S Sale
2.0
Malik Vikram
Non-Executive Director
28,000 -9.9%
12.93
US$362,012 		28,000 -9.9% 12.93 US$362,012
2024-05-15 2024-05-13 S Sale
2.2
GILL DAVID N
Non-Executive Director
3,643 -8.2%
12.72
US$46,356 		3,643 -8.2% 12.72 US$46,356
2024-05-14 2024-05-13 PrS Proposed sale
2.0
Malik Vikram

Director

Non-Executive Director
28,000
12.93
US$362,040 		28,000 12.93 US$362,040
2024-05-13 2024-05-13 PrS Proposed sale
2.2
GILL DAVID N

Director

Non-Executive Director
10,361
12.70
US$131,585 		10,361 12.70 US$131,585
2024-05-14 2024-05-10 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
16,051 -2.3%
12.72
US$204,127 		16,051 -2.3% 12.72 US$204,127
2024-05-14 2024-05-10 S Sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
2,423 -1.6%
12.72
US$30,814 		2,423 -1.6% 12.72 US$30,814
2024-05-14 2024-05-10 S Sale
3.3
Avelar Rui

See Remarks

Officer
3,441 -0.9%
12.72
US$43,761 		3,441 -0.9% 12.72 US$43,761
2024-03-29 2024-03-27 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
6,236 -0.9%
13.86
US$86,431 		6,236 -0.9% 13.86 US$86,431
2024-03-21 2024-03-19 S Sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
5,672 -3.5%
13.92
US$78,978 		5,672 -3.5% 13.92 US$78,978
2024-03-21 2024-03-19 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
96,566 -12.2%
13.92
US$1,344,604 		96,566 -12.2% 13.92 US$1,344,604
2024-03-21 2024-03-19 S Sale
3.3
Avelar Rui

See Remarks

Officer
27,603 -6.9%
13.92
US$384,350 		27,603 -6.9% 13.92 US$384,350
2024-02-23 2024-02-22 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
7,706 -1.0%
13.08
US$100,804 		7,706 -1.0% 13.08 US$100,804
2024-02-23 2024-02-22 PlS Planned sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
1,821 -1.1%
13.08
US$23,821 		1,821 -1.1% 13.08 US$23,821
2024-02-23 2024-02-22 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
1,821 -0.5%
13.08
US$23,821 		1,821 -0.5% 13.08 US$23,821
2024-02-02 2024-01-30 S Sale
2.3
Parschauer Karah Herdman
Non-Executive Director
11,931 -27.6%
13.14
US$156,733 		11,931 -27.6% 13.14 US$156,733
2024-01-30 2024-01-30 PrS Proposed sale
2.3
KARAH PARSCHAUER

Director

Non-Executive Director
11,931
13.14
US$156,732 		11,931 13.14 US$156,732
2023-12-08 2023-12-08 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
31,300 -4.9%
9.73
US$304,505 		31,300 -4.9% 9.73 US$304,505
2023-12-08 2023-12-06 S Sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
51,348 -7.5%
10.09
US$517,891 		51,348 -7.5% 10.09 US$517,891
2023-12-06 2023-12-06 PrS Proposed sale
2.9
MOATAZEDI DAVID

Officer

Officer
82,648
10.00
US$826,480 		82,648 10.00 US$826,480
2023-10-18 2023-10-16 S Sale
2.3
Medytox Inc.
1,690,663 -33.3%
7.50
US$12,679,972 		1,690,663 -33.3% 7.50 US$12,679,972
2023-09-08 2023-09-06 PlS Planned sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
3,178 -2.7%
9.70
US$30,827 		3,178 -2.7% 9.70 US$30,827
2023-08-16 2023-08-16 PlS Planned sale
3.3
Beaver Sandra

Chief Financial Officer

Officer
2,211 -1.9%
10.27
US$22,707 		2,211 -1.9% 10.27 US$22,707
2023-08-16 2023-08-16 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
14,778 -2.1%
10.27
US$151,770 		14,778 -2.1% 10.27 US$151,770
2023-08-16 2023-08-16 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
2,211 -0.6%
10.27
US$22,707 		2,211 -0.6% 10.27 US$22,707
2023-08-15 2023-08-15 B Purchase
2.0
Malik Vikram
Non-Executive Director
174,967 +174.0%
7.41
US$1,296,505 		174,967 +174.0% 7.41 US$1,296,505
2023-03-29 2023-03-27 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
6,110 -1.0%
8.47
US$51,752 		6,110 -1.0% 8.47 US$51,752
2023-03-16 2023-03-14 PlS Planned sale
3.3
Avelar Rui

See Remarks

Officer
14,906 -4.2%
8.47
US$126,237 		14,906 -4.2% 8.47 US$126,237
2023-03-16 2023-03-14 PlS Planned sale
2.9
MOATAZEDI DAVID

See Remarks

Executive Director
64,211 -9.4%
8.47
US$543,797 		64,211 -9.4% 8.47 US$543,797
2023-02-08 2023-02-07 S Sale
2.3
Medytox Inc.
Large shareholder
2,187,511 -30.1%
8.50
US$18,593,844 		2,187,511 -30.1% 8.50 US$18,593,844
2023-02-06 2023-01-20 S Sale
2.3
Medytox Inc.
Large shareholder
37,043 -0.5%
11.04
US$408,955 		37,043 -0.5% 11.04 US$408,955
2022-10-07 2022-10-06 S Sale
2.3
Medytox Inc.
Large shareholder
38,304 -0.5%
8.99
US$344,418 		38,304 -0.5% 8.99 US$344,418
2022-10-06 2022-10-05 S Sale
2.3
Medytox Inc.
Large shareholder
6,848 -0.1%
8.95
US$61,290 		6,848 -0.1% 8.95 US$61,290
2022-09-16 2022-09-15 S Sale
2.3
Medytox Inc.
Large shareholder
24,000 -0.3%
10.34
US$248,105 		24,000 -0.3% 10.34 US$248,105
2022-09-16 2022-09-14 S Sale
2.3
Medytox Inc.
Large shareholder
73,000 -1.0%
10.27
US$749,674 		73,000 -1.0% 10.27 US$749,674
2022-09-13 2022-09-12 B Purchase
0.9
HAYMAN ROBERT
Non-Executive Director
1,091 +12.2%
10.78
US$11,756 		1,091 +12.2% 10.78 US$11,756
2022-09-13 2022-09-09 B Purchase
0.9
HAYMAN ROBERT
Non-Executive Director
8,909 +inf%
10.35
US$92,182 		8,909 +inf% 10.35 US$92,182
2022-09-12 2022-09-09 S Sale
2.3
Medytox Inc.
Large shareholder
20,700 -0.3%
10.53
US$217,911 		20,700 -0.3% 10.53 US$217,911
2022-09-12 2022-09-08 S Sale
2.3
Medytox Inc.
Large shareholder
15,300 -0.2%
10.39
US$158,979 		15,300 -0.2% 10.39 US$158,979
Explore more

More insider trading research around Evolus Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America